arrow_back Trending Legislation
Share share

Stem Cell Therapies: Renewed Funding and Research Advancement

This act extends funding for stem cell treatment programs, meaning greater access to therapies for patients. It also introduces regular scientific reviews to ensure new treatment methods can be quickly integrated into programs. Additionally, the act aims to increase the availability of cord blood units, which can help more people in need of transplants.
Key points
Increased funding for stem cell treatment programs until 2026, enhancing access to innovative therapies.
Regular scientific reviews every 2 years to ensure new therapies from adult stem cells and birthing tissues can be quickly made available to patients.
Strengthened efforts to increase the availability of cord blood units, crucial for transplants.
A report assessing the demand for specialists in regenerative medicine, potentially impacting career development in this field.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
TRANSPLANT Act of 2021
Print number: S 288
Sponsor: Sen. Reed, Jack [D-RI]
Process start date: 2021-02-08
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Stem Cell Therapies: Renewed Funding and Research Advancement

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 288.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-02-08.

What are the main provisions?

Key points include:

  • Increased funding for stem cell treatment programs until 2026, enhancing access to innovative therapies.
  • Regular scientific reviews every 2 years to ensure new therapies from adult stem cells and birthing tissues can be quickly made available to patients.
  • Strengthened efforts to increase the availability of cord blood units, crucial for transplants.
  • A report assessing the demand for specialists in regenerative medicine, potentially impacting career development in this field.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Reed, Jack [D-RI].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of S 288

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health